Anju Software

Clinical intelligence has always sat behind two walls. A paywall. And a knowledge wall. The paywall kept out anyone without an enterprise budget. The knowledge wall kept out anyone without the time or expertise to navigate complex systems. The result? Entire groups, clinicians, academic researchers, consultants, emerging biotechs, making early-stage decisions with incomplete information, or no information at all. We wrote about why we built OpenTA, what it means for access to clinical intelligence, and how it fits alongside TA Scan as one ecosystem built for different depths. If you want to understand why OpenTA exists — this is the read. 👇 🔗 https://lnkd.in/eEQPryuK #OpenTA #ClinicalTrials #ClinicalDevelopment #LifeSciences #ClinicalIntelligence #TAScan

Booth 9. #ISMPP2026. One final look back - and a clear look ahead. Over the past few days, the Anju team had the privilege of connecting with medical publication professionals, scientific communications leaders, and medical affairs teams helping shape the next chapter of the field. The conversations were thoughtful, practical, and urgent in all the right ways. - How do publication teams scale without losing control? - How do teams choose the right journals, conferences, and authorities with more confidence? - How do plain language summaries reach the audiences they were created for? - How do open access, discoverability, and workflow visibility come together in real publication strategy? These are the questions publication teams are carrying into the future. And they the questions PubStrat MAX is built to help answer. We were also proud to contribute to the research conversation through Poster 41, presented by Rachel Sheldon, Minal Mahajan, PhD, and Amanda M. Kelly. Among the many posters featured at the Annual Meeting of ISMPP (International Society for Medical Publication Professionals), this work brought important focus to access, clarity, and the real-world reach of scientific communications. Thank you to everyone who visited Booth 9, joined a demo, asked sharp questions, played PubStrat Jenga, and shared what your teams are solving right now. ISMPP may be wrapped, but the momentum continues. Let's keep the conversation going. Greg Flett-Davies Naveena J Narayanan #MedPub #MedComms #MedicalAffairs #PublicationManagement #ScientificPublications

Today, we're launching OpenTA. The first look at a clinical trial landscape shouldn't require a full subscription, a demo call, or months of back-and-forth. OpenTA gives clinical teams, researchers, consultants, investigators - or anyone who's interested - immediate access to trial landscape intelligence, so the first decision can be a good one. No friction. No paywall to get started. https://openta.anjudp.com/ This is something we're genuinely proud of. Clinical trial planning starts with understanding — and that understanding should be accessible. #OpenTA #TAScan #ClinicalTrials #ClinicalIntelligence #Pharma #Biotech

Day 2 is underway at ISMPP (International Society for Medical Publication Professionals)! Live from Booth #9 in Washington, DC, Anju is giving attendees an early look at JSCA 2.0. Our Journal Selector and Conference Authority (JSCA) Database is Anju’s journals, societies, conferences, and intelligence platform, designed specifically for medical affairs and publication planning teams who need a clear, data-driven view of where to share their science. Today, teams use JSCA to search, analyze, and identify the right journals and conferences to reach their target audiences. That foundation already helps publication planning teams target more appropriate venues, align to key conference deadlines and journal lead times, and make smarter decisions with greater precision. Now, the next chapter is on the horizon. A few attendees are already getting a sneak peek at JSCA 2.0 — an even more intelligent evolution of Anju’s journals, conferences, and authorities capabilities, built to sharpen targeting and deliver smarter recommendations. If you’re at ISMPP, stop by Booth #9 to see what’s coming and connect with Rachel Sheldon, Greg Flett-Davies, and Naveena J Narayanan #ISMPP #MedicalAffairs #MedComms #PublicationManagement #ScientificPublications

Anju is kicking off ISMPP Day 1 with a bang. Coming in hot at ISMPP (International Society for Medical Publication Professionals): Poster 41 steps up today from 5:45-6:45 p.m ET. Topic: License to Engage: Open Access License Types and Real Reach of Plain Language Summaries Presented by Rachel Sheldon, and co-authored by Minal Mahajan and Amanda M. Kelly. Here's the tension at the heart of the matter: open access, plain language summaries, and what it really takes to expand the reach and real-world impact of scientific communications. If your team has been grappling with discoverability, accessibility, and real-world scientific communications impact, this is your chance to catch the latest solutions from Anju. Stop by Poster 41 and see the thinking behind the research up close. Then keep the momentum going at Booth #9, where the team is live with Pubstrat MAX and more! #ISMPP #MedicalAffairs #MedComms

Happening NOW: ISMPP (International Society for Medical Publication Professionals) in Washington, DC 👋 The Anju team is live at Booth #9 with Pubstrat MAX and ready to talk publication planning, workflow efficiency, and smarter scientific communications. Come meet: Greg Flett-Davies Rachel Sheldon Naveena J Narayanan Stop by to see how JSCA, Pubstrat MAX, CiteCentral help teams bring publication planning, execution, and knowledge management together in one connected ecosystem. If you're at ISMPP, come join the live action: - Meet the team - Get a live product walkthrough - Talk through your current publication workflow challenges - Take us on in a round of Pubstrat Jenga - Grab Anju giveaways while you're there Can't make it to the booth, or want a deeper follow-up after the event? Let's keep the conversation going. We've dropped a link for you to Request a Demo in the comments #ISMPP #MedicalAffairs #PublicationManagement #ScientificPublications #HealthTech

We are thrilled to be attending the 22nd Annual Meeting of ISMPP, April 20–22, in Washington, DC! The publication landscape is evolving faster than ever, and ISMPP is where we come to listen, learn, and connect with the people doing the work. It always brings out the best conversations in the field. Stop by Booth #9 to connect with our team and learn how Pubstrat MAX is helping publication teams simplify their journey in the middle of all that change. We look forward to seeing you in DC! ISMPP (International Society for Medical Publication Professionals) #ISMPP2026 #PubstratMAX #MedComms #MedPubs #PublicationManagement

Competition doesn't announce itself. It shows up in your enrollment numbers. In crowded therapeutic areas, the sites you planned on are already stretched. The geographies you targeted are already saturated. Competing sponsors got there first — and you're the last to know. Static trial registries tell you who started a study. They don't tell you where your recruitment plan is about to collide with someone else's. TA Scan's competitive intelligence module shows you the full picture: ▪️ Overlap detection across sites and countries running competing trials ▪️ Sponsor strategy profiles — cadence, phase distribution, geographic footprints ▪️ Site–sponsor competitive matrices showing saturation and engagement history ▪️ Dynamic dashboards that update as the landscape moves Better enrollment plans start with an honest competitive map. See the landscape before you finalize your strategy 👉 https://lnkd.in/eiPVKdn8 #CompetitiveIntelligence #ClinicalTrials #TrialPlanning #TAScan #Oncology

Most site lists still start with relationships and gut feel. Not with a question like: does this site actually have capacity right now? The result is predictable: ▪️ Sites that were willing to participate — not ready to recruit ▪️ Enrollment that starts slow and never catches up ▪️ Delays that were visible in the data long before FPI TA Scan's site selection module gives you a different starting point. A tiering system built on expertise. Capacity signals, not just historical activity. A site inference algorithm that surfaces up to 30% more viable sites than public records show. From thousands of options to a defensible shortlist — in days, not weeks. A top 10 pharma team said it best: it changed the time it takes to vet sites, and gave them an efficiency advantage in clinical operations. See how it works 👉 https://lnkd.in/eu5diJ6X #SiteSelection #ClinicalTrials #ClinicalOperations #TAScan #Feasibility